11:40 AM EDT, 10/06/2026 (MT Newswires) -- ViiV Healthcare's phase 3b study assessing its Cabenuva treatment in adults and adolescents with HIV-1 who had detectable virus when they entered the study met its primary endpoint, according to a Tuesday release. In the Crown trial, long-acting Cabenuva achieved superior rates of viral suppression at six months compared with standard-of-care oral antiretroviral therapy, according to a Tuesday release. The study enrolled 326 participants across eight countries. The specialist HIV company is majority-owned by GSK (GSK.L), with Shionogi as a shareholder.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.